Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 11/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30537240 | 1.00 | EPHX2 (0.43) | EPHX2EP300KAT2BKAT8KDM4E | |
| SCHEMBL4987598 | 0.83 | EPHX2 (0.43) | EPHX2EP300KAT2BKAT8KDM4E | |
| Bromide SCHEMBL30493633 | 0.82 | EPHX2 (0.42) | EPHX2EP300KAT2BKAT8KDM4E | |
| SCHEMBL1724416 | 0.75 | EPHX2 (0.43) | EPHX2EP300KAT2BKAT8KDM4E | |
| SCHEMBL10293735 | 0.75 | EPHX2 (0.43) | EPHX2KDM4EMAPKAPK2ACHE | |
| SCHEMBL468359 | 0.71 | ESR1 (0.53) | EPHX2ESR1ESR2HIF1A | |
| SCHEMBL18878981 | 0.71 | EPHX2 (0.54) | EPHX2EP300KAT2BKAT8HIF1A | |
| SCHEMBL14048220 | 0.71 | EPHX2 (0.40) | EPHX2EP300KAT2BKAT8KDM4E | |
| SCHEMBL10293445 | 0.71 | EPHX2 (0.40) | EPHX2EP300KAT2BKAT8 | |
| SCHEMBL14030285 | 0.71 | EPHX2 (0.43) | EPHX2EP300KAT2BKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269008-B2 | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions | FIBROGEN, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | HIF1AN, HIF1A, EGLN2 | EPHX2 1943/4885EP300 276/4885KAT2B 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.